文献速递肾癌与肾肿瘤

高危局限性肾癌的辅助治疗:新兴证据与未来临床试验

Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
PubMed 文献 · J Urol · 2017-05-04

本文综述高危局限性肾癌术后辅助治疗文献,将已发表的2项结果矛盾的前瞻性试验置于各自设计背景下分析,并聚焦基于新型免疫检查点抑制剂的在研试验。传统免疫治疗如干扰素-α和高剂量白细胞介素-2未能显示辅助治疗获益且伴显著不良事件;血管内皮生长因子和mTOR抑制剂数据矛盾,ASSURE试验发现索拉非尼或舒尼替尼较安慰剂无无复发生存获益,而S-TRAC试验显示1年舒尼替尼使无复发生存改善1.2年。

要点

  • 传统免疫治疗作为高危局限性肾癌术后辅助治疗似乎无作用。
  • S-TRAC提供证据表明1年辅助舒尼替尼增加较高危局限性疾病患者的中位复发时间。
  • 总生存数据不成熟且不良事件常见,免疫检查点抑制剂试验结果备受期待。

核心结论

  • 基于现有数据,传统免疫治疗作为高危局限性肾癌术后辅助治疗似乎无作用。
  • S-TRAC提供证据表明1年辅助舒尼替尼在较高危局限性疾病患者中增加中位复发时间。
  • 然而总生存数据不成熟且不良事件常见,免疫检查点抑制剂试验结果备受期待。

研究设计与样本

  • 本文为文献综述,检索PubMed截至2017年1月的英文文献,关键词为「肾细胞癌」「肾癌」「免疫治疗」「靶向治疗」和「辅助治疗」,并查询ClinicalTrials.gov进行中的研究。
  • 纳入近期在主要泌尿外科和肿瘤内科会议上展示的相关数据。
  • 将2项近期发表的结果矛盾的前瞻性试验在其各自设计背景下合并分析。

主要发现

  • 传统免疫治疗如干扰素-α和高剂量白细胞介素-2的若干试验未能证明辅助治疗获益,且与显著不良事件相关。
  • ASSURE试验(NCT00326898)发现索拉非尼或舒尼替尼较安慰剂无无复发生存获益。
  • S-TRAC试验(NCT00375674)显示1年舒尼替尼使无复发生存改善1.2年。
  • 疫苗为基础的治疗和抗体依赖性细胞毒药物结果不一。

关键数值与推荐

  • 辅助治疗可分为传统免疫治疗、血管内皮生长因子和mTOR通路抑制剂、疫苗和抗体依赖性细胞毒药物、免疫检查点抑制剂四类。
  • 血管内皮生长因子和mTOR抑制剂在转移性疾病中毒性较轻,因此是辅助试验的自然考虑。

临床怎么用

  • 基于现有数据,传统免疫治疗作为高危局限性肾癌术后辅助治疗似乎无作用。
  • S-TRAC提供证据表明1年辅助舒尼替尼在较高危局限性疾病患者中增加中位复发时间,但总生存数据不成熟且不良事件常见。
  • 未来辅助试验可能由分子特征指导以治疗最可能获益的患者。

局限性

  • 总生存数据不成熟。
  • 不良事件常见。
  • 当前血管内皮生长因子和mTOR抑制剂数据矛盾。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We reviewed the literature on adjuvant therapies for patients with high risk localized kidney cancer following surgical resection. In this analysis we merge 2 recently published prospective trials with conflicting results within the context of their respective designs. In addition, we spotlight upcoming trials that use novel immunotherapy based checkpoint inhibitors and have the potential to establish a new standard of care. MATERIALS AND METHODS: We searched PubMed® for English language articles published through January 2017 using the keywords "renal cell carcinoma," "kidney cancer," "immunotherapy," "targeted therapy" and "adjuvant therapy." ClinicalTrials.gov was queried for ongoing studies. Relevant data recently presented at major urology and medical oncology meetings are also included. RESULTS: Adjuvant therapies for high risk localized kidney cancer can be grouped into the categories of 1) traditional immunotherapy, 2) inhibitors of the vascular endothelial growth factor and mTOR (mammalian target of rapamycin) pathways, 3) vaccines and antibody dependent cytotoxic agents, and 4) immune checkpoint inhibitors. Several trials of traditional immunotherapy, such as interferon-α and high dose interleukin-2, failed to demonstrate benefit as adjuvant treatment and were associated with significant adverse events. Vascular endothelial growth factor and mTOR inhibitors have less severe toxicity in metastatic disease and, therefore, are natural considerations for adjuvant trials. However, current data are conflicting. The ASSURE (Sunitinib Malate or Sorafenib Tosylate in Treating Patients with Kidney Cancer that was Removed by Surgery, NCT00326898) trial found no recurrence-free survival benefit of sorafenib or sunitinib over placebo, while S-TRAC (Clinical Trial Comparing Efficacy and Safety of Sunitinib versus Placebo for the Treatment of Patients at High Risk of Recurrent Renal Cell Cancer, NCT00375674) revealed that 1 year of sunitinib improved recurrence-free survival by 1.2 years. Vaccine based treatments and antibody dependent cytotoxic agents have had mixed results. New trials evaluating immune checkpoint inhibitors are planned, given the impressive efficacy and tolerability as second line agents in metastatic disease. Future adjuvant trials are likely to be guided by molecular signatures to treat patients most likely to benefit. CONCLUSIONS: Based on the available data, there appears to be no role for traditional immunotherapy as adjuvant treatment in patients with high risk localized kidney cancer following surgical resection. S-TRAC provides evidence that 1 year of adjuvant sunitinib in patients with higher risk locoregional disease increases the median time to recurrence. However, the data on overall survival are immature and adverse effects are common. Results from trials investigating immune checkpoint inhibitors are highly anticipated.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lenis AT, Donin NM, Johnson DC, et al. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. J Urol. 2017. PMID: 28479237. doi:10.1016/j.juro.2017.04.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。